TABLE 1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies | Synapse

Cite This Study

Chan et al. (Thu,) studied this question.

synapsesocial.com/papers/68e781eeb6db6435876f4e80 https://doi.org/https://doi.org/10.1158/2767-9764.25266660

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TABLE 1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TABLE 1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024

2FIGURE 5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024

3Supplementary Figure S5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024

4Supplementary Methods from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024

5Supplementary Figure S4 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024